Armata Pharmaceuticals Inc
NYSE-MKT:ARMP
Intrinsic Value
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections... [ Read More ]
The intrinsic value of one
ARMP
stock under the Base Case scenario is
1.91
USD.
Compared to the current market price of 2.65 USD,
Armata Pharmaceuticals Inc
is
Overvalued by 28%.
ARMP's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ARMP or that its price is influenced by factors unrelated to fundamentals.
Armata Pharmaceuticals Inc's market capitalization is 95.8m USD.
ARMP stock price is 2.65 USD.
ARMP stock (1.91 USD) is 28% less than its price (2.65 USD).
ARMP. Open DCF Valuation
ARMP stock (1.91 USD) is 28% less than its price (2.65 USD). Open Relative Valuation
ARMP has upside potential of 208% compared to the average analyst price target.
Open Wall St Estimates
ARMP's Revenue has dropped by 7% over the past 12 months.
ARMP's ROE (Return on Equity) has significantly increased in the last 3 years from -67% to 467%.
ARMP's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -99% to -55%, and is approaching profitability.
ARMP has positive Net Debt. This means that the company has more debt (107m USD) than cash and short-term investments (38m USD).
ARMP's long-term liabilties (177m USD) exceed its long-term assets (120m USD).
ARMP's Revenue has been growing by an exceptional 36% per year for the last 3 years.
ARMP has negative Operating Income for the last twelve months.
ARMP has negative Net Income for the last twelve months.
ARMP's ROE (Return on Equity) for the past 12 months is very high and is equal to 467%.
ARMP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -55%.
ARMP's short-term liabilties (110m USD) exceed its short-term assets (42m USD).
ARMP has negative Free Cash Flow for the last twelve months.
ARMP has negative three-year average ROE (Return on Equity): -324%. The company is not efficient at transforming stockholders' equity into net income.
ARMP has negative three-year average ROIC (Return on Invested Capital): -66%. The company is not efficient at using invested capital to generate operating income.
ARMP's D/E (Debt to Equity) is very low and is equal to -1.89.
ARMP's Altman Z-Score is very low and is equal to -4.87.
Valuation Backtest
Armata Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
ARMP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Armata Pharmaceuticals Inc
Balance Sheet Decomposition
Armata Pharmaceuticals Inc
| Current Assets | 41.7m |
| Cash & Short-Term Investments | 37.9m |
| Receivables | 1.7m |
| Other Current Assets | 2.1m |
| Non-Current Assets | 78.6m |
| PP&E | 56.9m |
| Intangibles | 13.7m |
| Other Non-Current Assets | 8m |
| Current Liabilities | 110m |
| Accounts Payable | 3.9m |
| Accrued Liabilities | 9.2m |
| Short-Term Debt | 71.7m |
| Other Current Liabilities | 25.3m |
| Non-Current Liabilities | 66.8m |
| Long-Term Debt | 35.4m |
| Other Non-Current Liabilities | 31.5m |
Earnings Waterfall
Armata Pharmaceuticals Inc
|
Revenue
|
4.7m
USD
|
|
Operating Expenses
|
-48.3m
USD
|
|
Operating Income
|
-43.6m
USD
|
|
Other Expenses
|
-35.9m
USD
|
|
Net Income
|
-79.6m
USD
|
Free Cash Flow Analysis
Armata Pharmaceuticals Inc
ARMP Profitability Score
Profitability Due Diligence
Armata Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Armata Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
ARMP Solvency Score
Solvency Due Diligence
Armata Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Armata Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARMP Price Targets Summary
Armata Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ARMP
is 8.16 USD
with a low forecast of 7.07 USD and a high forecast of 9.45 USD.
Ownership
ARMP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ARMP Price
Armata Pharmaceuticals Inc
| Average Annual Return | 0.72% |
| Standard Deviation of Annual Returns | 71.91% |
| Max Drawdown | -85% |
| Market Capitalization | 95.8m USD |
| Shares Outstanding | 36 146 600 |
| Percentage of Shares Shorted | 0.09% |
Company Profile
Armata Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
Contact
IPO
Employees
Officers
The intrinsic value of one
ARMP
stock under the Base Case scenario is
1.91
USD.
Compared to the current market price of 2.65 USD,
Armata Pharmaceuticals Inc
is
Overvalued by 28%.
You don't have any saved screeners yet
